Anzeige
Mehr »
Samstag, 19.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
545 Leser
Artikel bewerten:
(2)

MMJ International Holdings: DEA Cannabis Poisoned, Zero Oversight-Massachusetts Lab Scandal: A Case Study in DEA's Regulatory Collapse

Poisoned Cannabis, Zero DEA Oversight

The DEA's mission statement is a sham under Thomas Prevoznik's watch. Americans are being poisoned by untested state cannabis operators while terminal patients are denied potential cures.

WASHINGTON, D.C. / ACCESS Newswire / July 6, 2025 / The Drug Enforcement Administration (DEA) exists to "prevent, detect, and investigate the diversion of controlled substances while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs". Yet under the leadership of Deputy Administrator Thomas Prevoznik, the DEA's Diversion Control Division has catastrophically failed this mission. Instead of protecting public health, the agency has allowed contaminated cannabis to flood state markets-poisoning consumers-while simultaneously blocking federally compliant pharmaceutical research that could save lives. This is not just bureaucratic incompetence; it is systemic negligence bordering on malpractice.

1. DEA's Mission Failure: Poisoned Cannabis, Zero Oversight

The Massachusetts Scandal: A Case Study in Regulatory Collapse

In Massachusetts, Assured Testing Laboratories-a facility responsible for testing 25% of the state's cannabis-was caught falsifying safety reports, concealing contamination, and approving products that should have failed for yeast, mold, and microbial toxins. Thousands of tainted products reached consumers, yet the DEA:

  • Took no enforcement action

  • Issued no national recall

  • Failed to intervene despite its mandate to prevent diversion and ensure safety.

This is not an isolated incident. Across the U.S., unregulated cannabis markets operate like the "Wild West"-with no federal quality control, no uniform safety standards, and no accountability. The DEA, under Prevoznik, has abdicated its duty, leaving Americans exposed to dangerous products while offering no recourse.

2. Blocking Medical Breakthroughs: The DEA's War on Science

While turning a blind eye to contaminated street cannabis, the DEA has actively obstructed federally approved pharmaceutical research. MMJ BioPharma, a company developing cannabis-based treatments for Huntington's Disease and Multiple Sclerosis, has faced seven years of bureaucratic sabotage despite:

  • Holding FDA Investigational New Drug (IND) approvals

  • Securing Orphan Drug Designation for Huntington's therapy

  • Passing DEA security inspections.

Yet, Prevoznik's division refuses to grant MMJ a bulk manufacturing license, citing a retroactive "Bona Fide Supply Agreement" (BFSA) requirement that creates an impossible Catch-22:

  • No supplier will sign a contract without DEA approval.

  • DEA won't approve without a signed contract.

This obstruction is not just regulatory failure-it's deliberate stonewalling. As MMJ's legal filings reveal, DEA Administrative Law Judges (ALJs) operate in a structurally biased system, where registrants win only 20-25% of cases, and the DEA overturns nearly all pro-registrant rulings.

3. The Human Cost: Patients Suffer While Illicit Markets Thrive

The DEA's hypocrisy is staggering:

  • Patients with epilepsy, cancer, and neurological disorders are denied access to standardized, pharmaceutical-grade cannabis112.

  • Meanwhile, unregulated THC products-laced with pesticides, mold, and heavy metals-flood the market, making consumers sick 15.

Prevoznik's DEA has created the worst of both worlds:
No protection for consumers from tainted products.
No pathway for research into life-saving medicines.

4. Time for Accountability: Fire Prevoznik, Overhaul the DEA

The solution is clear:

  1. Remove Thomas Prevoznik for gross negligence and regulatory malpractice.

  2. Transfer cannabis oversight to the FDA/NIH, where science-not stigma-guides policy.

  3. Investigate DEA's Diversion Control Division for systemic bias and corruption.

As MMJ BioPharma CEO Duane Boise stated:

"The DEA's Diversion Control Division, under Prevoznik's leadership, has failed to protect the public, failed to uphold science, and failed to meet even the most basic standards of competence."

Fire Thomas Prevoznik: A Call to Action

The DEA's mission statement is a sham under Prevoznik's watch. Americans are being poisoned by untested cannabis while terminal patients are denied potential cures. Congress must intervene, the courts must act, and the public must demand accountability.

Enough is enough. It's time to end the DEA's obstructionism and put public health over bureaucracy.

MMJ is Represented by Attorney Megan Sheahan and Associates

CONTACT:
Madison Hisey
media@mmjih.com
203-231-8583

SOURCE: MMJ International Holdings



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/dea-cannabis-poisoned-zero-oversight-massachusetts-lab-scandal-a-case-1045926

© 2025 ACCESS Newswire
Hensoldt, Renk & Rheinmetall teuer
Rheinmetall, Renk und Hensoldt haben den Rüstungsboom der letzten Jahre dominiert, doch inzwischen sind diese Titel fundamental heillos überbewertet. KGVs jenseits der 60, KUVs über 4, und das in einem politisch fragilen Umfeld mit wackelnder Haushaltsdisziplin. Für späteinsteigende Anleger kann das teuer werden.

Doch es gibt Alternativen, die bislang unter dem Radar fliegen; solide bewertet, operativ stark und mit Nachholpotenzial.

In unserem kostenlosen Report zeigen wir dir, welche 3 Rüstungsunternehmen noch Potenzial haben und wie du von der zweiten Welle der Zeitenwende profitieren kannst, ohne sich an überhitzten Highflyer zu verbrennen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders vom weltweiten Aufrüsten profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.